Literature DB >> 34230915

PML/RARA destabilization by hyperthermia: a new model for oncogenic fusion protein degradation?

Hsin Chieh Wu1,2, Domitille Rérolle1,2, Hugues de Thé3,2,4.   

Abstract

In this issue, Maimaitiyiming and colleagues demonstrate thermic stress-induced PML/RARA oncogenic fusion protein destabilization driven by corepressor aggregation. Hyperthermia synergizes with PML/RARA degradation by ATO and may circumvent ATO-resistance in historical APL patients. This novel approach could be extended to other corepressor-associated oncogenic fusion proteins.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34230915      PMCID： PMC7611121          DOI： 10.1158/2643-3230.BCD-21-0071

Source DB:  PubMed          Journal:  Blood Cancer Discov        ISSN： 2643-3230


  9 in total

Review 1.  Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure.

Authors:  Hugues de Thé; Pier Paolo Pandolfi; Zhu Chen
Journal:  Cancer Cell       Date:  2017-11-13       Impact factor: 31.743

2.  Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein.

Authors:  Pauline Isakson; Magnar Bjørås; Stig Ove Bøe; Anne Simonsen
Journal:  Blood       Date:  2010-06-23       Impact factor: 22.113

3.  Targeted protein degradation: expanding the toolbox.

Authors:  Matthieu Schapira; Matthew F Calabrese; Alex N Bullock; Craig M Crews
Journal:  Nat Rev Drug Discov       Date:  2019-10-30       Impact factor: 84.694

4.  Identification of a nuclear domain with deacetylase activity.

Authors:  M Downes; P Ordentlich; H Y Kao; J G Alvarez; R M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

5.  PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.

Authors:  Marion Jeanne; Valérie Lallemand-Breitenbach; Omar Ferhi; Marcel Koken; Morgane Le Bras; Stéphanie Duffort; Laurent Peres; Caroline Berthier; Hassane Soilihi; Brian Raught; Hugues de Thé
Journal:  Cancer Cell       Date:  2010-07-13       Impact factor: 31.743

6.  Point mutation in AML1 disrupts subnuclear targeting, prevents myeloid differentiation, and effects a transformation-like phenotype.

Authors:  Diana Vradii; Sayyed K Zaidi; Jane B Lian; Andre J van Wijnen; Janet L Stein; Gary S Stein
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-03       Impact factor: 11.205

7.  Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.

Authors:  Francesco Lo-Coco; Giuseppe Avvisati; Marco Vignetti; Christian Thiede; Sonia Maria Orlando; Simona Iacobelli; Felicetto Ferrara; Paola Fazi; Laura Cicconi; Eros Di Bona; Giorgina Specchia; Simona Sica; Mariadomenica Divona; Alessandro Levis; Walter Fiedler; Elisa Cerqui; Massimo Breccia; Giuseppe Fioritoni; Helmut R Salih; Mario Cazzola; Lorella Melillo; Angelo M Carella; Christian H Brandts; Enrica Morra; Marie von Lilienfeld-Toal; Bernd Hertenstein; Mohammed Wattad; Michael Lübbert; Matthias Hänel; Norbert Schmitz; Hartmut Link; Maria Grazia Kropp; Alessandro Rambaldi; Giorgio La Nasa; Mario Luppi; Fabio Ciceri; Olimpia Finizio; Adriano Venditti; Francesco Fabbiano; Konstanze Döhner; Michaela Sauer; Arnold Ganser; Sergio Amadori; Franco Mandelli; Hartmut Döhner; Gerhard Ehninger; Richard F Schlenk; Uwe Platzbecker
Journal:  N Engl J Med       Date:  2013-07-11       Impact factor: 91.245

8.  Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.

Authors:  Rihab Nasr; Marie-Claude Guillemin; Omar Ferhi; Hassan Soilihi; Laurent Peres; Caroline Berthier; Philippe Rousselot; Macarena Robledo-Sarmiento; Valérie Lallemand-Breitenbach; Bernard Gourmel; Dominique Vitoux; Pier Paolo Pandolfi; Cécile Rochette-Egly; Jun Zhu; Hugues de Thé
Journal:  Nat Med       Date:  2008-11-23       Impact factor: 53.440

9.  Fine tuning of the UPR by the ubiquitin ligases Siah1/2.

Authors:  Marzia Scortegagna; Hyungsoo Kim; Jian-Liang Li; Hang Yao; Laurence M Brill; Jaeseok Han; Eric Lau; David Bowtell; Gabriel Haddad; Randal J Kaufman; Ze'ev A Ronai
Journal:  PLoS Genet       Date:  2014-05-08       Impact factor: 5.917
  9 in total
  5 in total

1.  SUMOylation regulates the number and size of promyelocytic leukemia-nuclear bodies (PML-NBs) and arsenic perturbs SUMO dynamics on PML by insolubilizing PML in THP-1 cells.

Authors:  Seishiro Hirano; Osamu Udagawa
Journal:  Arch Toxicol       Date:  2022-01-10       Impact factor: 5.153

2.  Sacubitril/valsartan protects against arsenic trioxide induced cardiotoxicity in vivo and in vitro.

Authors:  Zhiqiang Wu; Hongzhu Chen; Liwang Lin; Jing Lu; Qilei Zhao; Zengxiang Dong; Xin Hai
Journal:  Toxicol Res (Camb)       Date:  2022-05-16       Impact factor: 2.680

3.  Hyperthermia promotes degradation of the acute promyelocytic leukemia driver oncoprotein ZBTB16/RARα.

Authors:  Qian-Qian Wang; Liaqat Hussain; Pei-Han Yu; Chang Yang; Chen-Ying Zhu; Ya-Fang Ma; Si-Chun Wang; Tao Yang; Yuan-Yuan Kang; Wen-Juan Yu; Yasen Maimaitiyiming; Hua Naranmandura
Journal:  Acta Pharmacol Sin       Date:  2022-10-10       Impact factor: 7.169

4.  Arsenic Trioxide Therapy During Pregnancy: ATO and Its Metabolites in Maternal Blood and Amniotic Fluid of Acute Promyelocytic Leukemia Patients.

Authors:  Meihua Guo; Jian Lv; Xiaotong Chen; Mengliang Wu; Qilei Zhao; Xin Hai
Journal:  Front Oncol       Date:  2022-05-12       Impact factor: 5.738

Review 5.  Magnetite Nanoparticles in Magnetic Hyperthermia and Cancer Therapies: Challenges and Perspectives.

Authors:  Agnieszka Włodarczyk; Szymon Gorgoń; Adrian Radoń; Karolina Bajdak-Rusinek
Journal:  Nanomaterials (Basel)       Date:  2022-05-25       Impact factor: 5.719
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.